The OncLive Pediatric Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of cancers in pediatric patients, including acute lymphoblastic leukemia, acute myeloid leukemia, brain cancers, sarcomas, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in childhood and adolescent and young adult cancers.
IKZF1 Deletions Predict Poor Prognosis in Pediatric ALLMarch 7th 2018
IKZF1 deletions that co-occurred with deletions in CDKN2A, CDKN2B, PAX5, or PAR1 in the absence of ERG deletion (IKZF1plus) were associated with a dramatically reduced prognosis in pediatric patients with B-cell precursor ALL.
Tisagenlecleucel Responses in Pediatric ALL Sustained With Longer Follow-upFebruary 1st 2018
At a median follow-up of 13.1 months, tisagenlecleucel (Kymriah) induced an overall remission rate of 81% in children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia.
Specialized Pediatric Palliative Care Teams Reduce High-Intensity Care at End of LifeJanuary 24th 2018
The presence of a specialized pediatric palliative care team lowered the odds that a child with cancer would be admitted to an intensive care unit at the end of life by five-fold compared with those who did not receive palliative care, according to results from a retrospective study.
Lymph Node/LOH Status Predict Survival in Wilms TumorJanuary 3rd 2018
In patients with stage III favorable-histology Wilms tumor, negative nodal involvement and the absence of loss of heterozygosity at chromosomes 1p and 16q were predictors for event-free survival and overall survival.
Dr. Andreadis on CAR T-Cell Therapy for Pediatric ALLDecember 29th 2017
Charalambos (Babis) Andreadis, MD, MSCE, associate professor of clinical medicine, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, discusses the role of chimeric antigen receptor (CAR) T-cell therapy for pediatric patients with acute lymphocytic leukemia (ALL).
Larotrectinib Rolling NDA Submission Initiated for TRK+ CancersDecember 20th 2017
Loxo Oncology has initiated a rolling submission of data for a NDA to the FDA for the novel pan-TRK inhibitor larotrectinib (LOXO-101) as a treatment for adult and pediatric patients with TRK fusion-positive advanced solid tumors.
Ipilimumab Approaches EU Approval for Pediatric MelanomaDecember 18th 2017
The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of ipilimumab for the treatment of pediatric patients aged 12 years and older with unresectable or metastatic melanoma.
Triplet Shows Promise in Pediatric Kaposi SarcomaDecember 14th 2017
Investigators working in Malawi found an association between the combination of vincristine, bleomycin, and etoposide and improved quality of life, overall survival, and event-free survival in children with Kaposi sarcoma
Palliative Care Opportunities Missed in Pediatric Hematology/OncologyNovember 30th 2017
Physicians are missing opportunities to refer pediatric patients with hematologic malignancies to palliative care at the end of life, and those who are admitted to palliative care tend to have very advanced disease.
Absolute Risk for Developing Most STS Low in Childhood Cancer SurvivorsNovember 29th 2017
While survivors of childhood cancers are at increased risk for developing soft-tissue sarcomas compared with the general population, the absolute risk for developing STS is low except for leiomyosarcoma after retinoblastoma.
Dr. Young on the Challenges of Using Anticoagulants in Children With CancerNovember 28th 2017
Guy Young, MD, director, Hemostasis and Thrombosis Program, attending physician, Hematology, Oncology and Blood and Marrow Transplantation, Children’s Hospital Los Angeles, discusses the challenges of using anticoagulants in children with cancer.
MRD, Genetic Classification Provide More Accurate Risk Stratification in Pediatric ALLNovember 17th 2017
Investigators working in the UK and Europe found a correlation between minimal residual disease kinetics and risk for relapse in pediatric patients with acute lymphoblastic leukemia.